Organization
Innovative Clinical Development
1 abstract
Abstract
A FIRST-IN-HUMAN, STUDY OF BMS-986165, A SELECTIVE, POTENT, ALLOSTERIC SMALL MOLECULE INHIBITOR OF TYROSINE KINASE 2 Org: Innovative Clinical Development, Clinical Pharmacology and Toxicology Department, Global Biometric Sciences, Bristol-Myers Squibb, Princeton, United States,